rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ZBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease

      - New patient and physician surveys reveal differing perspectives on disease burden, treatment goals, and long-term management - WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced The Distance Between platform and new findings from Zenas-sponsored patient and healthcare professional (HC

      Nov 17Yahoo FinanceZBIO
      Zenas BioPharma at Jefferies Global Healthcare Conference: launch, cash and pipeline
      Nov 16Investing.comZBIO
      Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference

      WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived repl

      Nov 9Yahoo FinanceZBIO
      Zenas BioPharma (ZBIO) After Third Quarter Losses Still Carries An Undervalued Narrative
      Nov 7Yahoo FinanceZBIO
      Zenas BioPharma launches new $200 million at-the-market stock offering
      Nov 6Investing.comZBIO
      Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 5Yahoo FinanceZBIO
      Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
      Oct 30Yahoo FinanceZBIO
      Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
      Oct 23Yahoo FinanceZBIO
      Zenas BioPharma Stock Gains Attention After Long Term Trial Data
      Oct 21Yahoo FinanceZBIO
      Morgan Stanley initiates Zenas Biopharma stock coverage with Equalweight rating
      Oct 20Investing.comZBIO
      H.C. Wainwright reiterates Zenas Biopharma stock rating at buy
      Oct 13Investing.comZBIO
      Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release
      Oct 13Yahoo FinanceZBIO
      Zenas BioPharma presents extended obexelimab data for IgG4-RD
      Oct 12Investing.comZBIO
      Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
      Oct 12Yahoo FinanceZBIO
      Zenas BioPharma to present MS research at Toronto conference
      Oct 7Investing.comZBIO
      Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

      WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada. The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) exper

      Oct 7Yahoo FinanceZBIO
      Zenas BioPharma to Host Virtual R&D Event
      Oct 6Yahoo FinanceZBIO
      Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (NASDAQ:ZBIO)

      Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date. Read why ZBIO stock is a Buy.

      Oct 5Seeking AlphaZBIO
      H.C. Wainwright reiterates Zenas Biopharma stock rating ahead of PDUFA
      Sep 30Investing.comZBIO
      Guggenheim reiterates Zenas Biopharma stock rating on IgG4-RD outlook
      Sep 30Investing.comZBIO
      Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
      Sep 23Yahoo FinanceZBIO
      Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?

      Zenas BioPharma (NasdaqGS:ZBIO) filed shelf registrations totaling more than US$240 million, according to recent regulatory disclosures. The filings include a broad shelf registration for potential future securities offerings across multiple instruments. A separate portion of the shelf is earmarked for an employee stock ownership plan related offering. The new shelf registrations and ESOP related shelf tell only part of the Zenas BioPharma story for investors to weigh. Our analysis turns up...

      Sep 23Yahoo FinanceZBIO
      Zenas BioPharma to present obexelimab IgG4-RD trial data
      Sep 22Investing.comZBIO
      Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
      Sep 22Yahoo FinanceZBIO
      Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase

      Sep 18Yahoo FinanceZBIO
      Zenas BioPharma at H.C. Wainwright conference: pipeline nears key tests
      Sep 16Investing.comZBIO
      Zenas BioPharma at Morgan Stanley conference: cash, pipeline and obexelimab
      Sep 14Investing.comZBIOMS
      Zenas BioPharma at Citi summit: pipeline bets and cash runway
      Sep 9Investing.comZBIO
      Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

      WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET. Zenas’ management team will be join

      Sep 8Yahoo FinanceZBIO
      Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

      WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ETMor

      Sep 4Yahoo FinanceZBIO

      This is the newest page. Registered accounts read further back.